CLINICAL TRIALS PROFILE FOR RANEXA
✉ Email this page to a colleague
All Clinical Trials for RANEXA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00099788 ↗ | Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes | Completed | The TIMI Study Group | Phase 3 | 2004-10-01 | MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo. |
NCT00099788 ↗ | Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes | Completed | Gilead Sciences | Phase 3 | 2004-10-01 | MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo. |
NCT00570089 ↗ | Microvascular Coronary Disease In Women: Impact Of Ranolazine | Completed | CV Therapeutics | Phase 2 | 2007-04-01 | 1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36). |
NCT00570089 ↗ | Microvascular Coronary Disease In Women: Impact Of Ranolazine | Completed | Cedars-Sinai Medical Center | Phase 2 | 2007-04-01 | 1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36). |
NCT00574756 ↗ | Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction | Terminated | University of California, San Diego | N/A | 2007-12-01 | The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography. |
NCT00832572 ↗ | Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy | Terminated | Gilead Sciences | Phase 4 | 2009-01-01 | This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks. |
NCT00914316 ↗ | Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities | Terminated | William Beaumont Hospitals | N/A | 2009-05-01 | The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. Investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. Lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RANEXA
Condition Name
Clinical Trial Locations for RANEXA
Trials by Country
Clinical Trial Progress for RANEXA
Clinical Trial Phase
Clinical Trial Sponsors for RANEXA
Sponsor Name